Clinical Trials Logo

Refractory AML clinical trials

View clinical trials related to Refractory AML.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05226468 Active, not recruiting - Clinical trials for Advanced Solid Tumor

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Start date: April 25, 2022
Phase: Phase 1
Study type: Interventional

This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01 and find out recommended dose of NEI-01 in solid tumor patient. Part 2: This part is extended dose design to determine the effectiveness of NEI-01 in in solid tumor and acute myeloid leukemia patients.

NCT ID: NCT04330820 Active, not recruiting - Relapsed Adult AML Clinical Trials

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

RELAX
Start date: April 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects with a histologically or cytologically confirmed acute myeloid leukemia who are refractory or suffered a relapse. This study will be conducted at multiple centers in Germany.